monoclonal antibodies or antigen-binding fragments thereof, pharmaceutical composition, and uses of monoclonal antibody or antigen-binding fragment thereof
GERHARD FREY,Hwai Wen Chang,PAMELA T. MANNING,WILLIAM A. FRAZIER
申请号：
BR112015013431
公开号：
BR112015013431A2
申请日:
2013.12.12
申请国别(地区):
BR
年份:
2017
代理人:
摘要：
monoclonal antibody or antigen binding fragment thereof； humanized or chimeric monoclonal antibody or antigen-binding fragment thereof； pharmaceutical composition； use； and humanized or chimeric monoclonal antibody, or antigen-binding fragment thereof, or competing monoclonal antibody, or antigen-binding fragment thereof, are provided monoclonal antibodies and antigen-binding fragments thereof which bind to and inhibit the activity of cd47 as well as monoclonal antibodies and antigen-binding fragments thereof which compete with the former for binding to cd47. combinations of any of the above are also provided. Such antibody compounds are variously effective in 1) treatment of tissue ischemia and ischemia-reperfusion injury (iri) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other cases. surgery and / or trauma where iri is a component of pathogenesis； 2) in the treatment of autoimmune and inflammatory diseases； and 3) as anticancer agents that are toxic to susceptible cancer cells by promoting (increasing) their phagocytic uptake and elimination, and / or directly killing such cells.resumo anticorpo monoclonal, ou respectivo fragmento ligante de antígenos； anticorpo monoclonal humanizado ou quimérico, ou respectivo fragmento ligante de antígenos； composição farmacêutica； uso； e anticorpo monoclonal humanizado ou quimérico, ou respectivo fragmento ligante de antígenos, ou anticorpo monoclonal competidor, ou respectivo fragmento ligante de antígenos são proporcionados anticorpos monoclonais e respectivos fragmentos ligantes de antígenos que se ligam a, e inibem a atividade de, cd47, bem como anticorpos monoclonais e respectivos fragmentos ligantes de antígenos que competem com os primeiros quanto a ligação a cd47. também são proporcionadas combinações de quaisquer dos anteriores. tais compostos de anticorpos são variadamente eficazes em 1) tratamento de isquemia tecidual e lesã
